Return On Capital Employed Overview: Teva Pharmaceutical Indus

Teva Pharmaceutical Indus TEVA posted Q2 earnings of $172.00 million, an increase from Q1 of 9.95%. Sales dropped to $3.87 billion, a 11.18% decrease between quarters. Teva Pharmaceutical Indus earned $191.00 million, and sales totaled $4.36 billion in Q1.

What Is Return On Capital Employed?

Changes in earnings and sales indicate shifts in Teva Pharmaceutical Indus’s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed in a business. Generally, a higher ROCE suggests successful growth in a company and is a sign of higher earnings per share for shareholders in the future. In Q2, Teva Pharmaceutical Indus posted an ROCE of 0.01%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For Teva Pharmaceutical Indus, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.

Q2 Earnings Recap

Teva Pharmaceutical Indus reported Q2 earnings per share at $0.55/share, which beat analyst predictions of $0.53/share.